Drug and Therapeutics Bulletin最新文献_第2页

Precision medicine arrives in COPD. 精准医疗降临COPD。

Drug and Therapeutics Bulletin Pub Date : 2026-09-03 DOI: 10.1136/dtb.2026.000039

Gordon Mallarkey

引用次数: 0

Management of urogenital gonococcal infection. 泌尿生殖系统淋球菌感染的处理。

Drug and Therapeutics Bulletin Pub Date : 2026-08-03 DOI: 10.1136/dtb.2025.000038

Soonita Oomeer

{"title":"Management of urogenital gonococcal infection.","authors":"Soonita Oomeer","doi":"10.1136/dtb.2025.000038","DOIUrl":"https://doi.org/10.1136/dtb.2025.000038","url":null,"abstract":"Gonorrhoea, caused by the bacterium Neisseria gonorrhoeae, is the second most common bacterial sexually transmitted infection diagnosed in the UK. Diagnoses remain highest among specific population groups: men who have sex with men, young people aged 15-24 years, and individuals of black Caribbean and mixed ethnicities. While most infections are asymptomatic, gonococcal infection can cause painful urogenital symptoms and, left untreated, can result in complications including pelvic inflammatory disease, epididymo-orchitis and infertility. Although infections can be treated successfully, there has been a concerning rise in diagnoses of antibiotic-resistant gonorrhoea in recent times. Treatment options are limited due to antimicrobial resistance and a lack of newer treatment options available. Sexual contacts should be treated if they test positive. Ceftriaxone remains a safe, effective first-line treatment. Ceftriaxone-resistant cases are being detected more frequently although numbers remain low in England and Wales. The recent roll-out of the world's first vaccination programme to protect against gonorrhoea infection is anticipated to save the NHS millions of pounds over the next decade. It remains to be seen whether this measure will effectively curb escalating national infection rates.","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discontinuation of levothyroxine in older adults. 老年人停用左甲状腺素。

Drug and Therapeutics Bulletin Pub Date : 2026-07-27 DOI: 10.1136/dtb.2026.000030

引用次数: 0

Update to the management of recurrent urinary tract infections in women aged 16 years and older. 16岁及以上妇女复发性尿路感染管理的最新进展。

Drug and Therapeutics Bulletin Pub Date : 2026-07-27 DOI: 10.1136/dtb.2025.000042

Leigh Sanyaolu, Haroon Ahmed, Miriam Santer, Sian Jones, Gail Hayward

{"title":"Update to the management of recurrent urinary tract infections in women aged 16 years and older.","authors":"Leigh Sanyaolu, Haroon Ahmed, Miriam Santer, Sian Jones, Gail Hayward","doi":"10.1136/dtb.2025.000042","DOIUrl":"10.1136/dtb.2025.000042","url":null,"abstract":"Recurrent urinary tract infections (rUTIs) are a burdensome condition affecting approximately 6% or 1.7 million women in the UK. UTIs are also a common reason for antibiotic use, with UK data demonstrating that they are the second most common reason for antibiotic prescribing after respiratory tract infections. UTIs also result in significant healthcare costs, with hospital admissions alone estimated to have cost the National Health Service in England over £600 million from 2023 to 2024. This review provides an up-to-date overview of the management of rUTIs, focusing on the updated 2024 National Institute for Health and Care Excellence guidance, which recommends a stepwise approach starting with behavioural measures, then progressing to non-antibiotic and finally antibiotic prevention. It also compares the guidance with international recommendations and outlines the current evidence on pathogenesis, diagnostic approaches and treatment options, including behavioural measures, non-antibiotic interventions (eg, vaginal oestrogen and methenamine hippurate) and antibiotic prophylaxis. Key challenges in primary care are discussed, such as diagnostic uncertainty, patient dissatisfaction and antimicrobial resistance (AMR). Emerging research in point-of-care testing, the urinary microbiome and novel therapies is also highlighted. This review aims to support safe prescribing, improve patient satisfaction and mitigate AMR by promoting antimicrobial and diagnostic stewardship in the management of rUTIs.","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"116-125"},"PeriodicalIF":0.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13479630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single National Formulary: solution or distraction? 单一国家处方：解决问题还是分散注意力？

Drug and Therapeutics Bulletin Pub Date : 2026-07-27 DOI: 10.1136/dtb.2026.000019

Sonali Sanghvi, Andrew Barron, John Minshull

引用次数: 0

Reducing thrombosis risk much earlier in pregnancy: the new NHS Maternal Care Bundle. 减少血栓形成的风险在怀孕早期：新的NHS孕产妇保健包。

Drug and Therapeutics Bulletin Pub Date : 2026-06-26 DOI: 10.1136/dtb.2025.000056

Joanna Girling

引用次数: 0

Dupilumab in chronic obstructive pulmonary disease. Dupilumab在慢性阻塞性肺疾病中的应用

Drug and Therapeutics Bulletin Pub Date : 2026-06-26 DOI: 10.1136/dtb.2026.000013

引用次数: 0

AIR and MART approach to asthma treatment. AIR和MART治疗哮喘的方法。

Drug and Therapeutics Bulletin Pub Date : 2026-06-26 DOI: 10.1136/dtb.2023.000058

Ruhi Bhugra

{"title":"AIR and MART approach to asthma treatment.","authors":"Ruhi Bhugra","doi":"10.1136/dtb.2023.000058","DOIUrl":"10.1136/dtb.2023.000058","url":null,"abstract":"Collaboration between the British Thoracic Society, National Institute for Health and Care Excellence and Scottish Intercollegiate Guidelines Network has resulted in a joint asthma guideline on the diagnosis, monitoring and management of chronic asthma. This marks a significant change in approach and brings the national asthma guideline in line with many of the recommendations made by the Global Initiative for Asthma. It is widely recognised that poor adherence to regular preventer treatment and overreliance on short-acting beta-2 agonists (SABAs), as highlighted by the recent Medicines and Healthcare products Regulatory Agency alert, may mask disease progression, leading to severe exacerbations with an increased risk of hospitalisation and mortality. To combat this, the national asthma guideline now advocates anti-inflammatory reliever (AIR) as the first step in those aged over 12 years. The guideline also promotes the use of maintenance and reliever therapy (MART) as second-line treatment or first-line for newly diagnosed asthma (in highly symptomatic patients or those presenting with a severe exacerbation). AIR and MART regimens ensure that patients receive both fast-acting formoterol and an inhaled corticosteroid with every dose, thereby treating the acute symptoms while also targeting the underlying airway inflammation respectively. AIR and MART provide potentially simpler asthma treatment plans for patients as they can be titrated according to patient needs, thereby addressing the overreliance on SABAs. Also, they reduce the carbon footprint associated with inhaler use by replacing the need for two inhalers (reliever and preventer).","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"108-111"},"PeriodicalIF":0.0,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147927497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Once-weekly insulin (insulin efsitora) for patients with type 2 diabetes. 2型糖尿病患者每周一次胰岛素（胰岛素注射）。

Drug and Therapeutics Bulletin Pub Date : 2026-06-26 DOI: 10.1136/dtb.2026.000022

Teck K Khong, Divyen Vanniasegaram

引用次数: 0

Understanding regression models in clinical research. 了解临床研究中的回归模型。

Drug and Therapeutics Bulletin Pub Date : 2026-05-28 DOI: 10.1136/dtb.2025.000032

Nazim Bhimani

引用次数: 0